OBJECTIVES: To evaluate the impact of subclinical hypothyroidism (sHT) treatment on health-related quality of life (QoL), psychiatric symptoms, clinical score, and muscle function. MATERIALS AND METHODS: In this randomized double-blind study, patients were assigned either to treatment (n = 35) or placebo (n = 36). Clinical and psychiatric symptoms were assessed by the Zulewski, Hamilton and Beck scales. QoL was assessed by the SF-36 questionnaire. Assessments of quadriceps (QS) and inspiratory muscle (IS) strength were performed by a chair dynamometer and a manuvacuometer. RESULTS: Treatment improved IS (+11.5 ± 17.2; p = 0.041), as did QoL domains "Pain" and "Role Physical" (+19.7 ± 15.2, 0.039 and +22.1 ± 47.5, p = 0.054; respectively). Clinical and psychiatric symptoms showed similar responses to both interventions. CONCLUSIONS:sHT treatment improved IS and physical aspects of QoL, despite no impact in other muscle parameters. Clinical score, psychiatric symptoms, and SF-36 domains, based on mental dimensions of QoL may be more susceptible to "placebo effect" in patients with sHT.
RCT Entities:
OBJECTIVES: To evaluate the impact of subclinical hypothyroidism (sHT) treatment on health-related quality of life (QoL), psychiatric symptoms, clinical score, and muscle function. MATERIALS AND METHODS: In this randomized double-blind study, patients were assigned either to treatment (n = 35) or placebo (n = 36). Clinical and psychiatric symptoms were assessed by the Zulewski, Hamilton and Beck scales. QoL was assessed by the SF-36 questionnaire. Assessments of quadriceps (QS) and inspiratory muscle (IS) strength were performed by a chair dynamometer and a manuvacuometer. RESULTS: Treatment improved IS (+11.5 ± 17.2; p = 0.041), as did QoL domains "Pain" and "Role Physical" (+19.7 ± 15.2, 0.039 and +22.1 ± 47.5, p = 0.054; respectively). Clinical and psychiatric symptoms showed similar responses to both interventions. CONCLUSIONS: sHT treatment improved IS and physical aspects of QoL, despite no impact in other muscle parameters. Clinical score, psychiatric symptoms, and SF-36 domains, based on mental dimensions of QoL may be more susceptible to "placebo effect" in patients with sHT.
Authors: Connie M Rhee; Yanjun Chen; Amy S You; Steven M Brunelli; Csaba P Kovesdy; Matthew J Budoff; Gregory A Brent; Kamyar Kalantar-Zadeh; Danh V Nguyen Journal: Clin J Am Soc Nephrol Date: 2017-07-13 Impact factor: 8.237
Authors: Martin Feller; Marieke Snel; Elisavet Moutzouri; Douglas C Bauer; Maria de Montmollin; Drahomir Aujesky; Ian Ford; Jacobijn Gussekloo; Patricia M Kearney; Simon Mooijaart; Terry Quinn; David Stott; Rudi Westendorp; Nicolas Rodondi; Olaf M Dekkers Journal: JAMA Date: 2018-10-02 Impact factor: 56.272
Authors: Richard Birtwhistle; Kate Morissette; James A Dickinson; Donna L Reynolds; Marc T Avey; Francesca Reyes Domingo; Rachel Rodin; Brett D Thombs Journal: CMAJ Date: 2019-11-18 Impact factor: 8.262